ArticleScientific reports2025
PHLDA1 silencing in IMR-32 human neuroblastoma cells results in ABCB1 overexpression, augments chemoresistance and leads to increased growth of tumors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PHLDA1 (pleckstrin homology-like domain, family A, member 1) is a multifunctional protein involved in pathophysiological conditions such as cancer. Our previous research revealed changes in the proteome of PHLDA1-silenced human neuroblastoma IMR-32 cells. One of the proteins that was increased in PHLDA1-silenced cells was the efflux pump ABCB1 (ATP binding cassette subfamily B member 1). In this study, ABCB1 efflux pump upregulation in PHLDA1-silenced IMR-32 cells led to increased resistance of the cells to xenobiotic agents. Experiments revealed that xenograft tumors grown in immunocompromised mice from PHLDA1-silenced cells presented multiple changes in comparison with tumors grown from control cells. Tumors grown from PHLDA1-silenced cells were larger and contained fewer apoptotic cells than control tumors. The blood vessels within the tumors grown from PHLDA1-silenced cells displayed increased extravasation and the extracellular matrix of the tumors presented increased collagen content in comparison to that of the control tumors. The results showed that silencing PHLDA1 in vivo promoted human neuroblastoma cell survival, decreased the apoptotic potential of the cells, disrupted angiogenesis in developing tumors, and altered collagen network formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.